Key Highlights

● ENDRA Life Sciences, a pre-revenue medical-imaging developer facing Nasdaq delisting, has agreed to merge with ASP Isotopes' Noble Africa unit and raise roughly $50 million, transforming into a helium-focused holding company renamed Noble Africa Inc.

● ENDRA's most recently disclosed stockholders' equity, as of December 31, 2025, was approximately $2.26 million, below Nasdaq's $2.5 million minimum requirement.

● ENDRA shareholders are being diluted to roughly 3% ownership of a business with no operating history in helium and none of the medical-device expertise that originally defined the company.

● Investors should watch for SEC review of the Form S-4 and ENDRA's stockholder vote on the merger.

ENDRA Life Sciences Inc. (Nasdaq: NDRA), developer of the pre-commercial TAEUS thermoacoustic liver-imaging platform, announced on June 25, 2026 that it had agreed to merge with Noble Africa LLC, a subsidiary of ASP Isotopes Inc. (Nasdaq: ASPI). The deal would leave ENDRA's medical-device business behind and convert the public shell into a helium-development company. Under terms disclosed jointly by ASP Isotopes and detailed in an ENDRA Form 8-K, the combined entity would be renamed Noble Africa Inc. and trade on Nasdaq under ticker "NOBA," with its principal asset being Renergen's Virginia Gas Project, a helium and natural gas development in South Africa's Free State province. The transaction is paired with an approximately $50 million concurrent private placement. This article separates confirmed structural and financial terms from the promotional framing surrounding the transaction.

What happened

ASP Isotopes announced that Noble Africa LLC, which holds its interest in Renergen, the South African helium and natural gas producer, would merge with a subsidiary of ENDRA, with Noble Africa surviving. Per ENDRA's Form 8-K, ASP Isotopes will contribute 100% of Renergen for 55.5 million Class B units of Noble, carrying ten votes per share versus one vote for Class A units, preserving ASP Isotopes' control. Noble is concurrently targeting roughly $50 million in gross proceeds through a private placement of Class A and Class B units priced at $6.57 each, with ASP Isotopes committing about $20 million, other investors roughly $30 million (including $750,000 from certain ASP officers and directors), earmarked for Phase 1 and Phase 2 development of the Virginia Gas Project. On a fully diluted basis, ASP Isotopes is expected to hold approximately 89% of the combined company, pre-closing ENDRA stockholders approximately 3%, and new placement investors approximately 7%.

Why the development matters

For ENDRA shareholders, this is less an operational milestone than an identity change. TAEUS, ENDRA's non-invasive device intended to measure liver fat, remains pre-revenue after years of development, and the company has separately struggled to maintain its Nasdaq listing on stockholders'-equity grounds. Rather than continue funding TAEUS, ENDRA's board proposes handing the public listing to a larger, revenue-stage natural-resources project. If completed, existing holders would retain only a small minority stake (about 3%) in a company with an entirely different business, management, and risk profile. Closing is not guaranteed: it requires ENDRA stockholder approval, SEC effectiveness of a Form S-4, Nasdaq approval of the new dual-class listing, completion of the $50 million financing, third-party consent tied to Renergen's existing financing agreements (referenced in filings as OPIC consent), and ENDRA maintaining a minimum $3.8 million in cash through closing, a threshold not assured given recent liquidity difficulties. A reverse split may also be required. The outside date is December 24, 2026, with parties targeting a third- or fourth-quarter close.

Company and product background

ENDRA has spent over a decade developing TAEUS (Thermo-Acoustic Enhanced UltraSound), intended to quantify liver fat non-invasively for fatty liver disease research and pharma/CRO markets. As of mid-2025 disclosures, TAEUS had generated no product revenue; management said it was "repositioning TAEUS for a subscription model targeting pharma/CROs," alongside smaller form factors, AI integration, and OEM licensing efforts, none yet disclosed as revenue-generating. ENDRA has also faced repeated Nasdaq listing challenges: an initial equity-deficiency notice on May 27, 2025, brief compliance around November 18, 2025, and a further notice on April 20, 2026 after reporting equity of $2,260,120 as of December 31, 2025, short of Nasdaq's $2.5 million minimum by $239,880. ENDRA says it will request a Nasdaq Hearings Panel hearing to pause delisting. Separately, in July 2025 ENDRA filed a Form S-1 for a roughly $121.4 million offering proposing to allocate about 95% of proceeds to a cryptocurrency treasury strategy, a pivot apparently superseded by the Noble Africa merger. Post-merger, the surviving business would be led by Paul E. Mann and Nick Mitchell, Renergen/ASP Isotopes executives.

Financial position

ENDRA's most recently disclosed stockholders' equity, as of December 31, 2025, was approximately $2.26 million, below Nasdaq's $2.5 million minimum. For the quarter ended June 30, 2025, operating loss was approximately $1.3 million, narrowed from about $2.2 million a year earlier, with no product revenue in either period. Detailed cash-on-hand figures from ENDRA's most recent 10-Q were not confirmed for this article; however, the merger's requirement that ENDRA maintain $3.8 million in cash through closing suggests liquidity remains a live closing risk. The $50 million placement is structured at the Noble Africa level, not as capital for ENDRA's legacy operations, and existing shareholders face substantial dilution to an estimated 3% stake.

Bull case

Supporters argue the transaction solves two problems in one step: a pre-revenue product with an uncertain commercial path, and a listing under chronic delisting pressure. By reverse-merging into Renergen's helium project, tied to a commodity facing tightening global supply, ENDRA shareholders gain indirect exposure to a larger, more advanced natural-resources business, with the combined company receiving an immediate $50 million capital injection rather than facing further dilutive financings to keep TAEUS alive.

Risk case

Critics note ENDRA shareholders are being diluted to roughly 3% ownership of a business with no operating history in helium and none of the medical-device expertise that originally attracted investors, with control concentrated in ASP Isotopes via a ten-vote Class B structure. The deal remains conditional and could fail to close, be delayed past its December 2026 outside date, or require a reverse split; ENDRA's chronic Nasdaq-equity shortfalls and its abandoned cryptocurrency-treasury proposal from mid-2025 suggest a pattern of shifting strategy under financial pressure. TAEUS's ultimate fate, sale, wind-down, or spin-out, is not detailed in filings reviewed for this article.

What investors should watch next

Key catalysts: SEC review of the Form S-4; ENDRA's stockholder vote on the merger; Nasdaq's decision on the new Class A/Class B listing (and any required reverse split); the outcome of ENDRA's Nasdaq Hearings Panel request; confirmation of ENDRA meeting the $3.8 million cash condition; and, if the deal closes, Noble Africa Inc.'s first disclosures as a helium-development company.

Conclusion

ENDRA's agreement to merge into Noble Africa is a confirmed, materially significant corporate action, verified through SEC filings and joint press releases, that would replace a struggling, pre-revenue medical-device company with a minority stake in a helium-development project controlled by ASP Isotopes. Numerous closing conditions, regulatory approvals, and a stockholder vote stand between announcement and completion, and the deal's value to current holders will depend on execution at Renergen's Virginia Gas Project rather than on anything ENDRA's legacy TAEUS business has yet achieved. This article draws no conclusion on investment merit.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.